← 返回前沿论文

四面体骨架核酸在骨科中的潜在应用

英文原题:Potential Applications of the Tetrahedral Framework Nucleic Acid in Orthopaedics.

PubMed 2026/08/31(内容时间) Curr Drug Metab Q3 · IF 2.3(JCR 2025)

研究概要

四面体框架核酸(tFNA)是一类特殊的三维DNA纳米结构,具有精确自组装、结构刚性、可编程性和优异的生物相容性。

中文摘要

四面体框架核酸(tFNA)是一类特殊的三维DNA纳米结构,具有精确的自组装能力、结构刚性、可编程性和优异的生物相容性。其独特的四面体几何结构使其能够抵抗酶降解,同时无需转染试剂即可实现高效的细胞内在化。因此,tFNA既可作为多功能调控因子,也可作为纳米载体。骨科愈合常因组织再生能力有限、炎症和感染难以预测以及复杂微环境中药物定位不理想而受阻。本综述总结了tFNA在骨科关键领域应用的最新进展,包括骨与软骨再生、血管生成、免疫调节、抗微生物治疗和骨癌治疗。研究表明,tFNA可通过间接激活Wnt/-catenin和PI3K/AKT通路,增强多种间充质干细胞群体的成骨和成软骨分化。当tFNA与肽、小分子、核酸或天然化合物功能化结合后,可促进血管生成、抑制氧化应激、抑制炎症和焦亡信号传导,并在退行性关节疾病中恢复细胞外基质稳态。此外,将tFNA与抗生素、抗菌肽、水凝胶和植入物表面相结合,在对抗骨科感染和生物膜形成方面展现出良好疗效,同时支持组织再生。新兴的基于tFNA的骨肉瘤治疗递送系统进一步展示了其转化应用的多样性。尽管这些发现令人鼓舞,但若干挑战阻碍了临床转化:大规模合成、长期生物安全性、免疫反应、药代动力学,以及在力学和生物学上复杂的骨科环境中的可控降解。跨学科研究和优化正在进行中,以推动基于tFNA的平台朝着骨科安全、有效和个性化的纳米治疗策略发展。这些进展最终可能重新定义用于全球肌肉骨骼疾病管理的精准疗法。

展开英文摘要原文

Tetrahedral framework nucleic acids (tFNA) are specialised three-dimensional DNA nanostructures with precise self-assembly, structural rigidity, programmability, and excellent biocompatibility. Their resistance to enzymatic degradation is enabled by their unique tetrahedral geometry, which also facilitates efficient cellular internalisation without the need for transfection agents. Thus, establishing tFNA as both a versatile regulator and a nanocarrier. Healing in orthopaedics is often stalled by limited tissue regeneration, unpredictable inflammation and infection, and suboptimal drug localisation within complex microenvironments. This review summarises recent advances in the application of tFNA across key orthopaedic domains, including bone and cartilage regeneration, angiogenesis, immunomodulation, anti-microbial therapy, and bone cancer treatment. tFNA have been shown to enhance osteogenic and chondrogenic differentiation of multiple mesenchymal stem cell populations by indirectly activating the Wnt/ -catenin and PI3K/AKT pathways. When functionalised with peptides, small molecules, nucleic acids, or natural compounds, tFNA promote angiogenesis, suppress oxidative stress, inhibit inflammatory and pyroptotic signalling, and restore extracellular matrix homeostasis in degenerative joint diseases. Furthermore, integration of tFNA with antibiotics, antimicrobial peptides, hydrogels, and implant surfaces demonstrates promising efficacy in combating orthopaedic infections and biofilm formation while supporting tissue regeneration. Emerging tFNA-based delivery systems for osteosarcoma therapy further illustrate their translational versatility. Despite these encouraging findings, several challenges hinder clinical translation: large-scale synthesis, long-term biosafety, immune responses, pharmacokinetics, and controlled degradation within mechanically and biologically complex orthopaedic environments. Interdisciplinary research and optimisation are ongoing to advance tFNA-based platforms toward safe, effective, and personalised nanotherapeutic strategies in orthopaedics. These developments may ultimately redefine precision therapies for the global management of musculoskeletal diseases.

论文信息

作者
Chen B
单位
Department of Medicine, Royal Alexandria Hospital, Paisley, United Kingdom.United Kingdom
期刊
Current drug metabolism2026 Aug 31
原文标识
PubMed 42708291 · DOI 10.2174/0113892002468732260816165149